The New England Journal of Medicine opinion piece is another sign of persistent furor over the agency’s decision.
For Robert Langreth's latest contributions to The Japan Times, see below:
Around the globe, people and governments are finding out that COVID-19 won’t be thrashed into extinction, but is more likely to enter a long, endemic tail.
The company plans to apply for regulatory clearance globally, with much of the first available doses going to low- and middle-income countries.
The approval appears to signal a fundamental shift in the way the FDA thinks about Alzheimer's disease, which could have lasting ramifications for other drugs in the pipeline.
Health officials are exploring whether and how an immune reaction may occur in people who have received vaccines made by AstraZeneca and Johnson & Johnson.
Mutations that likely confer partial resistance to vaccines and antibody treatments are now prevalent in both South Africa and Brazil, and they are threatening to spread worldwide.
Pfizer Inc. scaled back its COVID-19 production targets earlier this year after the drugmaker ran into difficulties securing all the materials it needs to produce the shots at a large scale.
The move came after a new analysis showed the vaccine was highly effective in preventing COVID-19 with no serious safety problems.
A briefing on Sunday included a series of inconsistent or misleading responses that left the country with an incomplete snapshot of Trump's health.
While broad correlation between ticks’ spread and global warming is clear, predicting where they will go next as the climate changes is surprisingly daunting.